Resource for Molecular Imaging Agents in Precision Medicine

总体资源：摘要 精准医学中分子成像剂的资源是一个跨越三个校区的计划， 约翰霍普金斯大学。在我们看来，精准医疗是利用手头上的所有数据， 患者，以便为该患者提供尽可能好的护理。我们相信精心设计的分子成像 代理商可以为此做出贡献。我们现在准备提供独特的生物医学技术资源中心 （BTRC），重点是提供化学-新试剂，方法和培训， 发展和实践-用于分子成像。BTRC的生物学主题是 癌症，炎症和免疫，对这些疾病的深入研究是一个未满足的需求。虽然出色的研究 在世界范围内继续开发新的分子成像剂，很少有实际的影响， 解决人类的弱点和许多弱点并不能证明其发展的成本是合理的。2014年3月，NIBIB 进行了一项研究，“以更好地了解为什么越来越多的分子成像剂和仪器， 在NIH的资助下开发的药物没有被转化为临床药物，也没有随后被商业化。到 为了解决这些缺点，JHU BTRC将通过利用翻译中心， 分子成像（CTMI）在约翰霍普金斯湾景医学院，F。M.柯比功能中心 脑成像在肯尼迪克里格研究所，癌症成像研究部， 核医学和分子成像，所有这些都高度集成到许多部门， 学校在JHU。我们已经生成了已获得许可并正在商业化的代理。 然而，迄今为止，这些活动是临时性的，我们打算扩大这些活动 以两种新的方式：（1）提供有针对性的和独特的技术研究和发展（TR&D）项目， (2)使其能够广泛传播和培训，提高各中心和部门的能力 如上所述，以执行其预期的功能-发现，旨在教育，促进新的合作， 跨学科研究和管理各种条件，同时解决意外的影响， 新兴的癌症免疫疗法。BTRC的独特之处在于它专注于提供新的，精确的 材料，对这些材料进行临床前测试，并将其用于人类使用，现场交付或交付给我们的合作者 以适合于其实施格式。我们将通过持续的、互惠的、 教育和“推拉”互动。该计划是不可知的成像方式和组成， 根据每个TR&D内的特定专业知识提供材料。除了分享目标之外， 利用化学成像，四个TR& D将通过上述生物主题联系起来。 他们可以简要地概括为新的治疗诊断学（TR&D 1），分子遗传成像系统 (TR免疫探测剂（TR&D 3）和化学交换饱和转移靶向剂 (CEST，TR&D 4）。TR& D 1和3中还分别包含临床前和临床验证核心。

OVERALL RESOURCE: Summary The Resource for Molecular Imaging Agents in Precision Medicine is a program spanning three campuses of the Johns Hopkins University (JHU). In our view precision medicine is using all data at hand regarding a particular patient to enable the best possible care for that patient. We believe that carefully designed molecular imaging agents can contribute to this. We are now poised to offer a unique Biomedical Technology Resource Center (BTRC) with a heavy emphasis on the provision of chemistry – new reagents, methods and training in their development and practice – for molecular imaging. The biological theme of the BTRC is relationships between cancer, inflammation and immunity, deeper study of which is an unmet need. Although brilliant research continues worldwide in the development of new molecular imaging agents, few have had actual impact on addressing human infirmity and many do not justify the cost of their development. In March 2014 the NIBIB conducted a study “to better understand the reasons why more molecular imaging agents and instrumentation developed with NIH grant support are not being translated to the clinic nor subsequently commercialized.” To address those shortcomings, the JHU BTRC will be highly translational by leveraging the Center for Translational Molecular Imaging (CTMI) at the Johns Hopkins Bayview medical campus, the F. M. Kirby Center for Functional Brain Imaging at the Kennedy Krieger Institute, the Division of Cancer Imaging Research, and the Division of Nuclear Medicine and Molecular Imaging, all of which are highly integrated into numerous departments and schools at JHU. We have generated agents that have been licensed and are in the process of commercialization. However to date those activities have been performed on an ad hoc basis, and we intend to expand upon them in two new ways: (1) provide targeted and unique technical research and development (TR&D) projects that will (2) enable widespread dissemination and training in their use, enhancing the capacity of the centers and divisions noted above to perform their intended functions – discovery with intent to educate, promote new collaborative, transdisciplinary research and to manage a variety of conditions, while addressing unanticipated effects of emerging cancer immunotherapies. The unique aspect of the BTRC is its focus on provision of new, precision materials, to test these pre-clinically and progress them to human use, delivered on-site or to our collaborators in a format suitable for their implementation. We will assure proper off-site utilization through continual, reciprocal education and “push-pull” interactions. The program is agnostic to imaging modality and composition of the materials to provide, relying upon the specific expertise within each TR&D. In addition to sharing the goal of leveraging chemistry for imaging, the four TR&Ds will be linked through the aforementioned biological theme. They can briefly be summarized as focusing on new theranostics (TR&D 1), molecular-genetic imaging systems (TR&D 2), agents for probing immunity (TR&D 3), and targeted agents for chemical exchange saturation transfer (CEST, TR&D 4). Within TR&Ds 1 and 3 are also the Pre-clinical and Clinical Validation cores, respectively.